BIOTECanada Release: Government of Canada Rare Disease Strategy Offers Hope and Solutions for Patients
Published: Oct 04, 2012
OTTAWA, Ontario--(BUSINESS WIRE)--BIOTECanada, the national industry association representing biotechnology companies today welcomed the Minister of Health’s announcement to create a Canadian orphan drug strategy. “With the creation of a regulatory pathway for rare disease medicines, the Government will be providing patients with greater access to innovative treatments addressing their unique medical needs. BIOTECanada strongly supports the Government’s initiative to make available to Canadian patients the best in rare disease patient care,” commented Andrew Casey, President and CEO of BIOTECanada, whose member companies are primary innovators and developers of the biologic medicines used in treating rare diseases.